

October 8, 2026

Dear Members and Friends of the Association for Creatine Deficiencies (ACD),

We hope this update finds you and your families well.

Many members of the CTD community attended the Cerebral Creatine Deficiency Syndromes (CCDS) Symposium in June, where Ultragenyx Founder and Chief Executive Officer Emil Kakkis shared an update on our creatine transporter deficiency (CTD) program. Because it has been some time since our last community update, we wanted to follow up and provide a summary of where the program stands today.

First and foremost, we want to thank the CTD community for your continued engagement, partnership, and patience. Over the years, families, caregivers, clinicians, researchers, and advocacy leaders have helped shape our understanding of CTD and informed our development efforts. Through advisory boards, caregiver research, the Vigilant natural history study, and ongoing conversations with the community, we have gained valuable insights that continue to influence our work. We remain committed to listening and learning, and we expect community engagement to remain an important part of the program as it moves forward. The ACD's efforts including the Creatine Info patient registry, Patient Focused Drug Development Meeting, and PaReNts project all are important resources that help advance understanding of CTD and the experiences of individuals and families living with the condition.

Our CTD program (UX068) continues to advance through the **preclinical stage of development**. In simple terms, this means the program is being evaluated in laboratory and nonclinical studies and has not yet been tested in people. At this stage, researchers are working to understand how this potential novel therapy may behave in the body, whether it appears to work as intended, and whether it has an acceptable safety profile to support future clinical studies for CTD. This is a critical step in the development of any potential medicine and helps determine whether a program is ready to advance into human clinical studies.

UX068, a small molecule, was designed to address the underlying biological challenge of CTD. Standard creatine supplements rely on the creatine transporter to carry creatine into cells, but that transporter is impaired in CTD. UX068 proposed mechanism is to help overcome that limitation by delivering creatine to neurons through a different pathway, with the goal of increasing creatine availability within brain cells.

We recognize the urgency families feel and the need for new treatment options. At the same time, we believe it is important to be transparent: there is still important work to do before UX068 could be studied in people. The priority is completing the studies needed to understand safety and determine whether the program should advance into clinical studies. If those studies are supportive, future clinical studies would first evaluate safety, tolerability, and dosing in healthy adults before starting clinical trials involving individuals living with CTD.



Going beyond every day.™

We are also pleased that ACD and Ultragenyx recently announced a partnership to support continued collaboration with the CTD community. We are grateful for the opportunity to work together and share a commitment to advancing understanding of CTD, supporting families, and helping ensure community perspectives continue to inform our efforts.

While there are still many questions to answer, our commitment to the CTD community remains unchanged. We are thankful for the trust the community has placed in us and for the many individuals and families who continue to contribute their experiences, insights, and time to help advance research. We will continue working diligently and will share future updates, as appropriate, as new information about the program becomes available.

Families and clinicians who would like to receive information about future program updates may contact trialrecruitment@ultragenyx.com.

Sincerely,

A handwritten signature in black ink that reads "Taylor Cusher". The signature is written in a cursive, flowing style.

Taylor Cusher
Director, Patient Advocacy
Ultragenyx